Pathogenesis of primary nonalcoholic fatty liver disease;Patogenia de la hepatopatía grasa no alcohólica primaria

Medicina Clinica

Volumn 124, Issue 17, 2005, Pages 668-677

  Moreno Sánchez, Diego ^a,b  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b CS Embajadores   (Spain)

Author keywords

Fatty liver; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

4 HYDROXYNONENAL; ADIPONECTIN; APOLIPOPROTEIN B100; CYTOKINE; FAS LIGAND; FREE RADICAL; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LIPOPROTEIN; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; ENDOTOXEMIA; FATTY ACID OMEGA OXIDATION; FATTY ACID OXIDATION; HUMAN; HYPERINSULINEMIA; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; KNOCKOUT MOUSE; KUPFFER CELL; LIPID PEROXIDATION; LIPOGENESIS; LIVER CELL DAMAGE; LIVER NECROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; RAT; REVIEW;

EID: 20844457615     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13074744     Document Type: Review

References (134)

1. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979;67:811-6.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
3. Cuevas J, Rull M, Pérez-Mateo M. Lesiones hepáticas infrecuentes en una paciente diabética. Gastroenterol Hepatol. 1981;4:161.
4. Moreno Sánchez D, Solís Herruzo JA, Vargas Castrillón J, Colina Ruiz-Delgado F, Lizasoain Hernández M. Esteatohepatitis no alcohólica. Estudio clinicoanalítico de 40 casos. Med Clin (Barc). 1987;89:188-93.
5. Vargas Castrillón J, Colina Ruiz-Delgado F, Moreno Sánchez D, Solís Herruzo JA. Esteatohepatitis no alcohólica. Estudio histopatológico de 40 casos. Med Clin (Barc). 1988;90:563-68.
6. Moreno Sánchez D. Esteatohepatitis no alcohólica. An Med Intern (Madrid). 1989;6:100-3.
7. Moreno Sánchez D, Castellano Tortajada G. El hígado en la obesidad. Gastroenterol Hepatol. 1993;16:550-8.
8. American Gastroenterological Association, American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1702-4.
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346: 1221-31.
10. Moreno Sánchez D, Casis Herce B, Martín Algíbez A, Nevado Santos M, Colina Ruiz-Delgado F, Galvao Filho O, et al. Esteatohepatitis no alcohólica. Evolución clínica e histológica a medio plazo de diez pacientes. Med Clin (Barc). 1991;96:733-6.
11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-9.
12. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-57.
13. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-19.
14. McCullough AJ. Natural history of nonalcoholic steatohepatitis. En: Arroyo V, Forns X, García-Pagán JC, editors. Progress in the treatment of liver diseases. Barcelona: Ars Medica, 2003; p. 219-25.
15. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs. 2003;63:2379-94.
16. Reaven GM. Syndrome X: 10 years after. Drugs. 1999;58 Supl 1:19-20.
17. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liv Dis. 2001;21:27-41.
18. Diehl AM. Nonalcoholic steatohepatitis pathogenesis. En: Arroyo V, Forns X, García-Pagán JC, editors. Progress in the treatment of liver diseases. Barcelona: Ars Medica, 2003; p. 227-32.
19. Day CP, James OFW. Steatohepatitis: a tale of two «hits»? Gastroenterology. 1998;114:842-5.
20. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002;10 Supl 2:975-1045.
21. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003; 37:909-16.
22. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology. 2003;38:1529-39.
23. Clarke SD. The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr Opin Lipidol. 2004;15:13-8.
24. Sanyal AJ. Insulin resistance and nonalcoholic steatohepatitis: fat or fiction. Am J Gastroenterol. 2001;96:274-6.
25. Harrison SA, Diehl AM. Fat and the liver: a molecular overview. Semin Gastrointest Dis. 2002;13:3-16.
26. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis. 2004;36:165-73.
27. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53 Supl 1:143-51.
28. Miner JL. The adipocyte as an endocrine cell. J Anim Sci. 2004;82: 935-41.
29. Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol. 2004;82:170-90.
30. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89:2583-9.
31. Bluher M, Khan BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003;299:572-4.
32. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-5.
33. Knobler H, Schattner A, Zhornicki T, Malnick SD, Ketter D, Sokolovskaya N, et al. Fatty liver: an additional and treatable feature of the insulin resistance syndrome. QJM. 1999;92:73-9.
34. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes. 2001;50:1844-50.
35. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. Am J Gastroenterol. 2001;96:2957-61.
36. Loguercio C, De Girolamo V, De Sio I, Tuccillo C, Ascione A, Baldi F, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol. 2001;25:568-74.
37. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology. 2002;35:373-9.
38. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistence, and metabolic syndrome. Further evidence for an etiologic association. Hepatology. 2002;35:367-72.
39. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-23.
40. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513-7.
41. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
42. Pirola L, Johnston AM, Van Obberghen E. Modulators of insulin action and their role in insulin resistance. Int J Obes Relat Metab Disord. 2003;27 Supl 3:61-4.
43. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540-3.
44. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis. 2001;21:89-104.
45. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet. 1996;13:18-9.
46. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467-76.
47. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
48. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548-51.
49. Neuschwander-Tetri BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep. 2002;4:31-6.
50. Barzilai N, Liu BQ, Vuguin P, Cohen P, Wang J, Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 1999;48:94-8.
51. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 1997;389:610-4.
52. Hotamisligil GS, Peraldi SP, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665-8.
53. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science, 2001;293:1673-7.
54. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437-46.
55. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002;122:274-80.
56. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science. 1996;274:1185-8.
57. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345-50.
58. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive leptin concentrations in normal weight and obese humans. N Engl J Med. 1996;334:292-5.
59. Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology. 1998;115:997-1001.
60. Uygun A, Kadayifici A, Yesilova G, Erdil A, Yaman H, Saka M, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2000;95:3584-9.
61. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations or the association between leptin and insulin resistance. FASEB J. 2002;16:1163-76.
62. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98:2771-6.
63. López-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W, et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf). 2004;60:256-63.
64. Hug C, Lodish HF. Diabetes, obesity and acrp30/adiponectin. Biotechniques. 2002;33:654-62.
65. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, et al. Modulation of circulating and adipose tissue adiponectine levels by antidiabetic therapy. Diabetes. 2003;52:667-74.
66. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:200-6.
67. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003;27 Supl 3:6-11.
68. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821-30.
69. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003;52:2784-9.
70. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, et al. Tissue-specific over-expression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA. 2001;98:7522-7.
71. Lundgren M, Eriksson JW. No in vitro effects of fatty acids on glucose uptake, lipolysis or insulin signaling in rat adipocytes. Horm Metab Res. 2004;36:203-9.
72. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-52.
73. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898-904.
74. Cohen P, Ntambi JM, Friedman JM. Stearoyl-CoA desaturase-1 and the metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord. 2003;3:271-80.
75. Miele L, Grieco A, Armuzzi A, Candelli M, Zocco MA, Forgione A, et al. Nonalcoholic steatohepatitis (NASH) and hepatic mitochondrial beta-oxidation [resumen]. J Hepatol. 2003;38 Supl 2:197.
76. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis. 2001;21:43-55.
77. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord. 2003;27 Supl 3:17-21
78. Haluzik M, Gavrilova O, LeRoith D. Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Endocrinology. 2004;145:1662-67.
79. Yeon JE, Choi KM, Baik SH, Kim KO, Lim HJ, Park KH, et al. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2004;19:799-804.
80. Perlemuter G, Corre MP, Conti M, Davit-Spraul A, Cosson C, Oppert JM, et al. Increase of liver anti-oxidant enzyme activities in non-alcoholic steatohepatitis (NASH): a defense against an oxidative stress [resumen]. J Hepatol. 2003;38 Supl 2:201.
81. Chavin KD, Yang SQ, Lin HZ, Chatham J, Chacko VP, Hoek JB, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 1999;274:5692-700.
82. Mataix J, Salas J. Obesidad. En: Mataix Verdú J, editor. Nutrición y alimentación humana. II. Situaciones fisiológicas y patológicas. Madrid. Ergon; 2002:1081-107.
83. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999;282:1659-64.
84. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999;31:430-4.
85. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120:1183-92.
86. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, Yamamoto T, et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol. 2004;6:351-7.
87. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345-53.
88. Den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol. 2004;24:544-9.
89. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80.
90. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998;27:128-33.
91. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067-75.
92. Lieber CS. CYP2E1: from ASH to NASH. Hepatol. Res 2004;28:1-11.
93. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 2003;37:544-50.
94. Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology. 2003;38:428-35.
95. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liv Dis. 2001;21:57-69.
96. Mataix J, Battino M. Estrés oxidativo. En: Mataix Verdú J, editor. Nutrición y alimentación humana. II. Situaciones fisiológicas y patológicas. Madrid: Ergon, 2002; p. 1047-63.
97. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutrition Rev. 2002;60:289-93.
98. Laurent A, Nicco C, Tran Van Nhieu J, Borderie D, Chereau C, Conti F, et al. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology. 2004;39:1277-85.
99. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-28.
100. Zhang-Gouillon ZQ, Yuan QX, Hu B, Marceau N, French BA, Gaal K, et al. Mallory body formation by ethanol feeding in drug induced mice. Hepatology. 1998;27:116-22.
101. Parola M, Pinzani M, Casini A, Albato E, Poli G, Gentilini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen α1(1) gene expression in human liver fat-storing cells. Biochem Biophys Res Comm. 1993;194:1044-50.
102. Bedossa P, Houglum K, Trautwein C, Holstege A, Chojkier M. Stimulation of collagen alpha 1 (1) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis? Hepatology. 1994;19:1262-71.
103. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, et al. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor b1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J. 1997;11:851-7.
104. Curzio M, Esterbauer H, Dianzani MU. Chemotactic activity of hydroxyalkenals on rat neutrophils. Int J Tissue React. 1985;7:137-42.
105. Pérez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martín A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38:999-1007.
106. Magnusson C, Vaux DL. Signaling by CD95 and TNF receptors; not only life and death. Immunol Cell Biol. 1999;77:41-6.
107. Houglum K, Buck M, Adir V, Chojkier M. LAP (NF-IL6) transactivates the collagen alpha 1 (1) gene from a 5' regulatory region. J Clin Invest. 1994;94:808-14.
108. Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, et al. Gene expression of TNFα and TNF receptors, p55 and p75, in non alcoholic steatohepatitis. Hepatology. 2001;34:1158-63.
109. Lancaster JR Jr, Laster SM, Gooding LR. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS Lett. 1989; 248:169-74.
110. Inayat-Hussain SH, Couet C, Cohen GM, Cain K. Processing/activation of CPP32-like proteases is involved in transforming growth factor β1-induced apoptosis in rat hepatocytes. Hepatology. 1997;25:1516-26.
111. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGFα and collagen type 1 is mediated by oxidative stress through c-myb expression. J Clin Invest. 1995;96:2461-8.
112. Hug H, Strand S, Grambihler A, Galle J, Hack V, Stremmel W, et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem. 1997;272:28191-3.
113. Pessayre D, Haouzi D, Fau D, Robin MA, Mansouri A, Berson A. Withdrawal of life support, altruistic suicide, fratricidal killing, and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. J Hepatol. 1999;31:760-70.
114. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatoheoatitis. Gastroenterology. 2003;125:437-43.
115. Vendemiale G, Grattagliano I, Caraceni P, Caraccio G, Domenicale M, Dall'Agata M, et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology. 2001;33:808-15.
116. Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004;34:57-62.
117. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 1993;328:1828-33.
118. Washington K, Wright K, Shyr Y, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol. 2000;31:822-8.
119. Anania FA. Leptin, liver, and obese mice: fibrosis in the fat lane. Hepatology. 2002;36:246-8.
120. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002;37:206-13.
121. Potter JJ, Womack L, Mezey E. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun. 1998;244:178-82.
122. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean litter-mates of ob/ob mice. Hepatology. 2002;35:762-71.
123. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002;122:1399-410.
124. Lee F-Y, Li Y, Yang EK, Yang SQ, Lin HZ, Trush MA, et al. Phenotypic abnormalities in macrophages from leptin deficient, obese mice. Am J Physiol Cell Physiol. 1999;276:C386-C94.
125. Diehl AM. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol. 2002;282:G1-G5.
126. Li Z, Lin H, Yang S, Diehl AM. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroentrology. 2002;123:1304-10.
127. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA. 1997;94:2557-62.
128. Nair S, Cope K, Risby TH, Diehl AM, Terence RH. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:1200-04.
129. Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology. 1988;36:349-51.
130. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998; 12:57-65.
131. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206-11.
132. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol. 2003;30:137-44.
133. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep. 2003;5:18-25.
134. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179-87.